(Reuters) ? Pfizer's Inlyta drug for patients with advanced kidney cancer got the nod from U.S. regulators on Friday, boosting the company's plans to offset plunging Lipitor sales.
The Food and Drug Administration said the drug, known generically as axitinib, was effective at treating patients who did not respond to another drug for kidney cancer.
About 61,000 Americans were diagnosed with kidney cancer last year, and about one in five of them are expected to die from the disease, according to the American Cancer Society.
About 20 percent to 30 percent of these patients have advanced disease at the time of diagnosis, Pfizer said.
Inlyta, which inhibits certain receptors that can influence tumor growth and progression of cancer, is one of several new drugs Pfizer is banking on to help replace lost revenue from its cholesterol fighter, Lipitor. The world's top-selling drug began facing generic competition late last year.
(Reporting by Anna Yukhananov in Washington and Anand Basu in Bangalore)
steelers vs broncos rupaul meet the press barry sanders barry sanders jay z chris herren
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন